Yingli Pharmaceutical's pan-KRAS mutation inhibitor is the first to be approved for clinical trials in the United States [Google translation] (Stockstar) - Jul 4, 2023 - "On July 3, 2023, the new pan-KRAS mutation small molecule inhibitor drug independently developed by Shanghai Yingli Pharmaceutical Co., Ltd. was approved by the US FDA for clinical trials, and phase 1 clinical studies will be carried out in the United States in the near future....The clinically approved product is YL-17231, a pan-KRAS mutant oral small molecule inhibitor combined with the KRAS switch II pocket, jointly developed by Yingli Pharmaceutical and its wholly-owned subsidiary 280Bio...Next, 280Bio will join hands with Dr. David Hong, a world-renowned clinical oncology researcher at the University of Texas MD Anderson Cancer Center, to advance the Phase 1 clinical trial of YL-17231 and recruit subjects in the fourth quarter of this year."
IND • New P1 trial • Oncology • Solid Tumor
|